Corning Sinks After Q1 Beat as Softer Q2 Guidance Disappoints Investors
Corning beat Q1 estimates but gave weak Q2 outlook, so shares fell despite strong year-to-date gains.
Already have an account? Sign in.
Corning beat Q1 estimates but gave weak Q2 outlook, so shares fell despite strong year-to-date gains.
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.